CLINICAL STUDY Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes

Objective: Vascular endothelial growth factor (VEGF) exists in three main splice variants, characterized by 121, 165 and 189 amino acids (VEGF 121, VEGF 165 and VEGF 189) and acts via two specific receptors: VEGF-R1 or Flt-1 and VEGF-R2 or KDR. VEGF plays an important role in the pathogenesis of diabetic retinopathy. This study examined the relationship between VEGF and its isoforms and the severity of diabetic nephropathy in type 2 diabetes. Design: We evaluated the glomerular gene expression of VEGF and its receptors and studied the relationships with renal functional and structural parameters in type 2 diabetic patients. Methods: Glomeruli from 17 kidney biopsies were microdissected; 14 out of 17 biopsies were also subjected to electron microscopic morphometric analysis to estimate glomerular structural parameters. VEGF mRNA was studied by comparative kinetic RT-PCR and real-time RT-PCR in order to identify the three different isoforms and to quantify VEGF, VEGF-R1 and VEGF-R2 mRNA levels. Results: (i) Glomerular VEGF mRNA levels were inversely related to albumin excretion rate (r 1⁄4 20.66, P 1⁄4 0.004); (ii) both the degree of mesangial and mesangial matrix expansion were inversely related to VEGF 165 mRNA levels (r 1⁄4 20.73, P 1⁄4 0.005 and r 1⁄4 20.64, P 1⁄4 0.017), and directly to VEGF 121 mRNA levels (r 1⁄4 0.74, P 1⁄4 0.003 and r 1⁄4 0.73, P 1⁄4 0.004); and (iii) VEGF and VEGF-R2 mRNA levels were directly related (r 1⁄4 0.62, P 1⁄4 0.033). Conclusions: These findings suggested that quantitative and qualitative changes in VEGF expression are present in type 2 diabetic patients with nephropathy and might be involved in the pathogenesis and progression of diabetic glomerulopathy. European Journal of Endocrinology 150 799–807